CMX 2043

Drug Profile

CMX 2043

Alternative Names: CMX-2043

Latest Information Update: 09 May 2016

Price : $50

At a glance

  • Originator Ischemix
  • Class Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Proto oncogene protein c akt modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Reperfusion injury

Most Recent Events

  • 03 May 2016 The phase IIa CARIN trial in Reperfusion injury (Prevention) did not meet the pre-specified endpoints
  • 09 Dec 2015 Ischemix receives patent allowance for CMX-2043 in New Zealand
  • 30 Sep 2015 Ischemix completes enrolment in the phase IIa CARIN trial for Reperfusion injury (Prevention) in USA and Canada (NCT02103959,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top